Market Overview:
The global early cancer screening tests market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, growing awareness about early cancer detection and screening tests, and technological advancements in the field of early cancer detection. The global early cancer screening tests market is segmented on the basis of type into liquid biopsy test and traditional biopsy. The liquid biopsy test segment is expected to grow at a higher CAGR than the traditional biopsy segment during the forecast period from 2018 to 2030. This can be attributed to technological advancements in this field that have made these tests more accurate and efficient than traditional methods for detecting cancers at an earlier stage. On the basis of application, the global early cancer screening tests market is divided into hospital, clinic, lab, and other segments. The hospital segment accounted for a major share of this market in 2017 owing to rising demand for these screenings from patients as well as healthcare providers across hospitals worldwide.
Product Definition:
Screening tests are used to identify cancer in people who don't have any symptoms. Screening tests may include a physical exam, blood test, or imaging test.
Liquid Biopsy Test:
Liquid biopsy test is a new and growing field of medical diagnostics. It's majorly used for the diagnosis of cancer, but it also helps in other chronic diseases like cardiovascular diseases, infections etc. This test involves blood tests along with imaging tests that can identify the areas or organs that are diseased or damaged.
Traditional Biopsy:
Traditional Biopsy is a method of obtaining tissue or fluid from the body for examination under a microscope. It's an invasive procedure and can be performed by medical professionals, usually doctors, as well as trained laypersons. The traditional biopsy technique is considered to be one of the most effective ways to obtain samples for laboratory testing in determining the presence or absence of cancerous cells in tissues and fluids such as urine, blood, bone marrow aspirate (BSA), sputum etc.
Application Insights:
The hospital-based application segment dominated the global early cancer screening tests market in 2017. This can be attributed to factors such as availability of advanced healthcare facilities and highly skilled medical personnel, which facilitate effective diagnosis. Moreover, rising awareness among patients regarding early detection of cancer is also expected to drive the segment growth over the forecast period. The other-than-hospital based clinics and laboratories segments are anticipated to witness substantial growth during the study period owing to increasing demand for sensitive diagnostic procedures that do not require a large number of biopsies or surgical interventions at a time when conventional methods fail to provide an accurate diagnosis due these types of cancers at an early stage.
For instance, while endoscopy is considered as one of the most efficient ways for diagnosing colorectal cancer, it cannot be used for breast or prostate cancer due its risk associated with internal injuries caused by sharp objects inside body organs such as colon or prostate respectively (neoplasm).
Regional Analysis:
North America dominated the global early cancer screening tests market in 2017. This can be attributed to the presence of key players, high adoption rate of technologically advanced products, and supportive government initiatives. For instance, in September 2018, Quest Diagnostics launched COVID-19 rapid diagnostic test for public health emergency under the “Testing It For Us†campaign. The company is also collaborating with non-profit organizations such as American Cancer Society to increase awareness about this emerging disease and encourage people to get tested as soon as possible.
Asia Pacific is expected to grow at a lucrative CAGR during the forecast period owing to increasing prevalence of cancer among Asian population coupled with growing disposable income & healthcare expenditure ratio per capita in countries like China & India. Moreover, rising investments by companies for expansion into untapped areas are anticipated to fuel growth over next eight years (2018 - 2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the early cancer screening tests market. According to the World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths from cancer worldwide. This number is expected to increase to 21 million new cases and 13 million deaths by 2030. Thus, the increasing incidence of cancer is driving the demand for early detection tests and therapies, which in turn is propelling the growth of the early cancer screening tests market.
- Rising awareness about benefits of early detection: There has been a rising awareness among people about benefits associated with early detection of cancers such as improved prognosis and treatment outcomes, reduced treatment costs, etc. This is encouraging people to undergo regular screenings for various types of cancers including breast, cervical, colorectal, prostate cancers etc., thereby propelling growth prospects for global Early Cancer Screening Tests market during forecast period 2016-2026 .
Scope Of The Report
Report Attributes
Report Details
Report Title
Early Cancer Screening Tests Market Research Report
By Type
Liquid Biopsy Test, Traditional Biopsy
By Application
Hospital, Clinic, Lab, Other
By Companies
GRAIL, Thrive Early Early Detection, Guardant Health, Amgen, Savor Health, Siemens, Philips, Canon Medical Systems, Hitachi, Esaote, Agilent Technologies, Abbott, Beckman Coulter, QIAGEN, R-Biopharm, Sysmex
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
128
Number of Tables & Figures
90
Customization Available
Yes, the report can be customized as per your need.
Global Early Cancer Screening Tests Market Report Segments:
The global Early Cancer Screening Tests market is segmented on the basis of:
Types
Liquid Biopsy Test, Traditional Biopsy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Lab, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GRAIL
- Thrive Early Early Detection
- Guardant Health
- Amgen
- Savor Health
- Siemens
- Philips
- Canon Medical Systems
- Hitachi
- Esaote
- Agilent Technologies
- Abbott
- Beckman Coulter
- QIAGEN
- R-Biopharm
- Sysmex
Highlights of The Early Cancer Screening Tests Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Liquid Biopsy Test
- Traditional Biopsy
- By Application:
- Hospital
- Clinic
- Lab
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Early Cancer Screening Tests Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Early cancer screening tests are screenings that can be done in your doctor's office or other health care setting to help detect cancer early. Some of the most common early cancer screening tests include:nnCancer risk assessments : A Cancer Risk Assessment (CRA) is a simple, painless test that can help you learn your individual risk for developing certain types of cancers. A CRA may also suggest additional screenings and preventive measures, such as regular checkups and vaccinations.nn: A Cancer Risk Assessment (CRA) is a simple, painless test that can help you learn your individual risk for developing certain types of cancers. A CRA may also suggest additional screenings and preventive measures, such as regular checkups and vaccinations. Breast exams : Women should have a breast exam every year starting at age 40 to screen for breast cancer . The American College of Obstetricians and Gynecologists recommends doing self-exams once every two months beginning at age 50 . If there are any changes or concerns about the appearance or feel of the breasts, women should see their doctor immediately . mammography : Mammography is an effective way to screen women for breast cancer , but it doesn't always find tumors early enough to save lives . It's important to talk with your doctor about which type(s) of mammography would be best for you based on your personal medical history , family history , age , race/ethnicity , etc.
Some of the major players in the early cancer screening tests market are GRAIL, Thrive Early Early Detection, Guardant Health, Amgen, Savor Health, Siemens, Philips, Canon Medical Systems, Hitachi, Esaote, Agilent Technologies, Abbott, Beckman Coulter, QIAGEN, R-Biopharm, Sysmex.
The early cancer screening tests market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Early Cancer Screening Tests Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Early Cancer Screening Tests Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Early Cancer Screening Tests Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Early Cancer Screening Tests Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Early Cancer Screening Tests Market Size & Forecast, 2018-2028
4.5.1 Early Cancer Screening Tests Market Size and Y-o-Y Growth
4.5.2 Early Cancer Screening Tests Market Absolute $ Opportunity
Chapter 5 Global Early Cancer Screening Tests Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Early Cancer Screening Tests Market Size Forecast by Type
5.2.1 Liquid Biopsy Test
5.2.2 Traditional Biopsy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Early Cancer Screening Tests Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Early Cancer Screening Tests Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Lab
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Early Cancer Screening Tests Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Early Cancer Screening Tests Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Early Cancer Screening Tests Analysis and Forecast
9.1 Introduction
9.2 North America Early Cancer Screening Tests Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Early Cancer Screening Tests Market Size Forecast by Type
9.6.1 Liquid Biopsy Test
9.6.2 Traditional Biopsy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Early Cancer Screening Tests Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Lab
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Early Cancer Screening Tests Analysis and Forecast
10.1 Introduction
10.2 Europe Early Cancer Screening Tests Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Early Cancer Screening Tests Market Size Forecast by Type
10.6.1 Liquid Biopsy Test
10.6.2 Traditional Biopsy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Early Cancer Screening Tests Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Lab
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Early Cancer Screening Tests Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Early Cancer Screening Tests Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Early Cancer Screening Tests Market Size Forecast by Type
11.6.1 Liquid Biopsy Test
11.6.2 Traditional Biopsy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Early Cancer Screening Tests Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Lab
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Early Cancer Screening Tests Analysis and Forecast
12.1 Introduction
12.2 Latin America Early Cancer Screening Tests Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Early Cancer Screening Tests Market Size Forecast by Type
12.6.1 Liquid Biopsy Test
12.6.2 Traditional Biopsy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Early Cancer Screening Tests Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Lab
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Early Cancer Screening Tests Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Early Cancer Screening Tests Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Early Cancer Screening Tests Market Size Forecast by Type
13.6.1 Liquid Biopsy Test
13.6.2 Traditional Biopsy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Early Cancer Screening Tests Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Lab
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Early Cancer Screening Tests Market: Competitive Dashboard
14.2 Global Early Cancer Screening Tests Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GRAIL
14.3.2 Thrive Early Early Detection
14.3.3 Guardant Health
14.3.4 Amgen
14.3.5 Savor Health
14.3.6 Siemens
14.3.7 Philips
14.3.8 Canon Medical Systems
14.3.9 Hitachi
14.3.10 Esaote
14.3.11 Agilent Technologies
14.3.12 Abbott
14.3.13 Beckman Coulter
14.3.14 QIAGEN
14.3.15 R-Biopharm
14.3.16 Sysmex
